DURECT Corp (DRRX) Reports Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Topline data anticipated in Q4 2023
CUPERTINO, Calif., June 7, 2023 /PRNewswire/ DURECT Corporation , a biopharmaceutical company developing epigenetic therapies for the treatment of acute organ. | June 7, 2023
Operator: Greetings, and welcome to the DURECT Corporation Fourth Quarter 2022 Earnings Call. . I will now turn the conference over to our host, Tim Papp, Chief Financial Officer. Thank you.